Literature DB >> 15356137

Dual function of the extracellular matrix: stimulatory for cell cycle progression of naive T cells and antiapoptotic for tissue-derived memory T cells.

Andreas Sturm1, Kimberley A Krivacic, Claudio Fiocchi, Alan D Levine.   

Abstract

Tissue T cells encounter Ag in a distinct microenvironment, where they are embedded in the interstitial extracellular matrix (ECM). In contrast, while naive T cells are exposed to Ag in the lymph node, immediately after naive T cells are activated they must extravasate into the ECM to function effectively. Because integrin-mediated adhesion to the ECM modulates cell cycle progression and survival in adherent nonimmune cells, we hypothesize that blood and tissue-derived T cells have similarly adapted their behavior to their first or continued encounter with ECM. T cells from peripheral blood (PBT) and tissue (the intestinal lamina propria T cell (LPT)) were stimulated with anti-CD3-coated beads in the presence or absence of native ECM derived from intestinal fibroblasts, plate-immobilized fibronectin, or collagen type I. Native ECM and collagen, but not fibronectin, induced in anti-CD3 activated PBT a 4- to 5-fold increase in the entry, progression, and completion of the cell cycle over that triggered by anti-CD3 alone. Neutralizing beta1 integrin Abs abrogated this increase. None of these ECM proteins stimulated cell cycle progression in LPT. In contrast, anti-CD3 activation of LPT in the presence of native ECM and fibronectin reduced activation-induced cell death by 40%. These results demonstrate that naive and effector/memory T cells respond differently upon exposure to specific ECM components. When naive PBT encounter Ag in the context of ECM, their progression through the cell cycle is enhanced, favoring clonal expansion; while tissue T cell longevity may be mediated by interactions with the ECM. Copyright 2004 The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15356137     DOI: 10.4049/jimmunol.173.6.3889

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  7 in total

1.  T cells and stromal fibroblasts in human tumor microenvironments represent potential therapeutic targets.

Authors:  Jennifer L Barnas; Michelle R Simpson-Abelson; Sandra J Yokota; Raymond J Kelleher; Richard B Bankert
Journal:  Cancer Microenviron       Date:  2010-03-31

Review 2.  Cancer-associated fibroblasts as targets for immunotherapy.

Authors:  Sunitha Kakarla; Xiao-Tong Song; Stephen Gottschalk
Journal:  Immunotherapy       Date:  2012-11       Impact factor: 4.196

3.  Probiotic sonicates selectively induce mucosal immune cells apoptosis through ceramide generation via neutral sphingomyelinase.

Authors:  Sandra Angulo; Albert Morales; Silvio Danese; Laura Llacuna; Maria Carme Masamunt; Nicole Pultz; Maria Grazia Cifone; Claudio De Simone; Salvadora Delgado; Jordi Vila; Julián Panés; Curtis Donskey; Jose C Fernández-Checa; Claudio Fiocchi; Miquel Sans
Journal:  PLoS One       Date:  2011-03-09       Impact factor: 3.240

4.  Identification and characterisation of an iron-responsive candidate probiotic.

Authors:  Jennifer R Bailey; Christopher S J Probert; Tristan A Cogan
Journal:  PLoS One       Date:  2011-10-19       Impact factor: 3.240

5.  Vitronectin in human hepatic tumours contributes to the recruitment of lymphocytes in an alpha v beta3-independent manner.

Authors:  S Edwards; P F Lalor; C Tuncer; D H Adams
Journal:  Br J Cancer       Date:  2006-11-07       Impact factor: 7.640

6.  Embryonic Fibroblasts Promote Antitumor Cytotoxic Effects of CD8+ T Cells.

Authors:  Yingyu Qin; Jung Hoon Shin; Jeong-Ho Yoon; Se-Ho Park
Journal:  Front Immunol       Date:  2018-04-13       Impact factor: 7.561

7.  NIH3T3 Directs Memory-Fated CTL Programming and Represses High Expression of PD-1 on Antitumor CTLs.

Authors:  Yingyu Qin; Yuna Lee; Jaeho Seo; Taehyun Kim; Jung Hoon Shin; Se-Ho Park
Journal:  Front Immunol       Date:  2019-04-11       Impact factor: 7.561

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.